Michael Sheikh - 25 Oct 2024 Form 4/A - Amendment Insider Report for BIOXYTRAN, INC (BIXT)

Reporting relationship
CCO, 10%+ Owner
Issuer ticker
BIXT
Reported as of
25 Oct 2024
Net transaction value
+$3,605,022
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4/A - Amendment
Accepted by SEC
18 Nov 2025, 15:45:11 UTC
Original report date
25 Oct 2024
Prior SEC filing
20 Aug 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Michael Sheikh

Key filing fact

Michael Sheikh filed Form 4/A - Amendment for BIOXYTRAN, INC (BIXT) on 18 Nov 2025.

Key facts

  • This page summarizes Michael Sheikh's Form 4/A - Amendment filing for BIOXYTRAN, INC (BIXT).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 18 Nov 2025, 15:45.

Change

  • Previous filing in this sequence was filed on 20 Aug 2024.
  • Current net transaction value: +$3,605,022.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001640636 Primary reporting owner

Sheikh Michael

Relationship
CCO, 10%+ Owner
Address
1905 S AUDUBON CT, SPOKANE
Signature
Michael Sheikh
Signature date
18 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BIXT transaction

preferred

Other

Transaction value
$3,605,022
Shares
+6,614,720
Change %
+413%
Price
$0.5450
Shares after
8,214,720
Date
25 Oct 2024
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares were issued as payment for the sale of NDPD Pharma to Bioxytran

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .